Company

PharmAust Limited

Headquarters: Bentley, WA, Australia

CEO: Dr. Roger Aston B.Sc., BSc (Hons), Ph.D.

ASX: PAA

Market Cap

A$48.1 Million

AUD as of Jan. 1, 2024

US$32.8 Million

Market Cap History

PharmAust Limited market capitalization over time

Evolution of PharmAust Limited market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

Market Cap History of PharmAust Limited

Detailed Description

PharmAust Limited, a clinical-stage company, develops targeted cancer therapeutics for humans and animals. The company develops drugs for the treatment of various cancers, and viral and neurological diseases. Its lead candidate is Monepantel (MPL), a small molecule drug for the treatment of cancer. PharmAust has completed Phase 1 clinical trials with monepantel in human and dog diagnosed with solid tumors, as well as initiated a Phase 2 pilot study in dogs diagnosed with Lymphoma. The company also provides products and services in synthetic and medicinal chemistry to the drug discovery and pharmaceutical industries worldwide. The company has a research agreement with the Walter and Eliza Hall Institute to investigate the effects of MPL upon human T-lymphotrophic virus-1 (HTLV-1) infections in vitro. It serves drug discovery and pharmaceutical industries. PharmAust Limited was incorporated in 2000 and is based in Bentley, Australia.

Top 1-year algo backtest: +284.14%

$10,000 in April 2023 would now be $38,414 by following this algorithm daily at market close.

Boost your stocks returns with Disfold AI... Now!

Try Disfold AI for FREE

Stocks & Indices

PharmAust Limited has the following listings and related stock indices.


Stock: ASX: PAA wb_incandescent

Details

Headquarters:

5/3 Brodie Hall Drive

Bentley, WA 6102

Australia

Phone: 61 8 9202 6814

Fax: 61 8 9467 6111